dm+d

Unassigned

New Medicines

Relapsing, recurrent multiple sclerosis (MS)

Information

New molecular entity
Sanofi
Sanofi

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Selective small molecule Bruton tyrosine kinase (BTK) inhibitor that can penetrate brain tissue
The prevalence of MS in the UK increased by about 2.4% per year from 1990 to 2010 reaching 285.8 per 100 000 in women and 113.1 per 100 000 in men by 2010 [2].
Relapsing, recurrent multiple sclerosis (MS)
Oral

Primary progressive multiple sclerosis (PPMS)

Information

New molecular entity
Sanofi
Sanofi

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Selective small molecule Bruton tyrosine kinase (BTK) inhibitor that can penetrate brain tissue
About 1 in 1,000 population have MS. 10-15% of sufferers have primary progressive sub-type and at onset [3].
Primary progressive multiple sclerosis (PPMS)
Oral

Secondary progressive, non-relapsing multiple sclerosis (MS)

Information

New molecular entity
Sanofi
Sanofi

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Selective small molecule Bruton tyrosine kinase (BTK) inhibitor that can penetrate brain tissue
Prevalence of MS in England is about 164 per 100,000 (Wales slightly lower, N. Ireland and Scotland higher). About 85% will have relapsing-remitting MS (RRMS) at onset but about 75% will eventually develop secondary progressive MS (about 50% within 10 years). In England, about 45% of those with MS have secondary progressive disease (about 40,000 patients) [3].
Secondary progressive, non-relapsing multiple sclerosis (MS)
Oral